antibody-recruiting molecules exploit endogenous antibodies for anti-tumor
NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and thru transendocytosis into ligand cells Aberrant NOTCH3 signaling and overexpression is oncogenic, related with most cancers stem cells and drug resistance, but therapeutic concentrating on stays elusive. Right here, we develop NOTCH3-targeted antibody drug conjugates (NOTCH3-ADCs) by bioconjugation of an auristatin microtubule inhibitor…